E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
male breast cancer patients |
|
E.1.1.1 | Medical condition in easily understood language |
male breast cancer patients |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the safety profile (AEs, SAEs) on combined treatment with tamoxifen and testosterone. |
|
E.2.2 | Secondary objectives of the trial |
• AR to ER ratio on baseline FES- and FDHT-PET imaging (assessed per lesion and per patient by quantitative analysis using standardized uptake values (SUV) and/or tumor tissue (assessed by percentage of ER and AR expression).
• Treatment response on 8 weeks FDG-PET/CT.
• Relation between baseline imaging and tumor characteristics to treatment response.
• Difference in adverse events between the two testosterone dosages.
• Increase in free testosterone levels, related to treatment response and toxicity.
• Monitoring of blood hematocrite, related to testosterone treatment.
• CtDNA for ER mutation analysis and CTCs (for ER and AR expression) at baseline, prior to cycle 2 and 3, related to response and FES- and FDHT PET imaging.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male
2. A history of proven ER+ (>10% of cells), AR+ (>10% of cells), and HER2- metastatic BC
3. Tumor progression after at least one line of conventional endocrine therapy
(tamoxifen, AI, fulvestrant, CDK4/6, ±LHRH analogue).
4. Age ≥ 18 years
5. Adequate hematological, renal and liver function as follows:
• Absolute neutrophil count > 1.5 x 109/L
• Platelet count >100 x 109/L
• White blood cell count >3 x 109/L
• AST and ALT <2.5 or <5.0 in case of liver metastases x upper limit of normal (ULN)
• Creatinine clearance >50mL/min
• Prothrombin time, partial thromboplastin time and INR <1.5 x ULN
6. Written informed consent
|
|
E.4 | Principal exclusion criteria |
1. History of prostate, testicular or liver cancer
2. Patients already using testosterone supplements
3. Patients using medication with anti-androgenic effects (e.g. spironolactone)
4. Elevated PSA (>4μg/L) or severe urinary tract problems (as defined with a Prostate Symptom Score >19). Patients with known BRCA mutation and PSA 3 μg/L will be referred to the urologist for prostate cancer screening, and can participate if they have no signs of prostate cancer.
5. Hematocrit >50%
6. Patients with uncontrolled hypertension, diabetes mellitus or other
significant cardiovascular morbidity.
7. Patients with recent history of coronary artery disease or trombo-embolic
events within 6 months prior to screening
8. Severe concurrent disease, infection, co morbid condition that, in the
judgment of the investigator would make the patient inappropriate for
enrollment
9. Visceral crisis and/or rapid progression necessitating chemotherapy
10. Previous allergic reaction to androgen agonists
11. Contra-indication for PET imaging
12. Tamoxifen or fulvestrant treatment <5 weeks prior to FES-PET.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety profile, defined as the number of AEs and SAEs that occur while on tamoxifen and testosterone treatment. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Safety evaluation will take place at least after 2 weeks, 4 weeks and 8 weeks. After this safety evaluations will take place at least every 4 to 12 weeks depending on the outcome of the prior evaluations. |
|
E.5.2 | Secondary end point(s) |
• AR to ER ratio on baseline FES- and FDHT-PET imaging (assessed per lesion and per patient by quantitative analysis using standardized uptake values (SUV)) and/or tumor tissue (assessed by percentage of ER and AR expression).
• Treatment response on 8 weeks FDG-PET/CT (assessed per lesion and per patient by quantitative analysis using standardized uptake values (SUV).
• Relation between baseline imaging and tumor characteristics to treatment response.
• Difference in adverse events between the two testosterone dosages.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
FES- and FHDT-PET will take place at baseline before the start of treatment.
For treatment response the first evaluation with FDG-PET/CT takes place after 2 cycli (8 weeks), after this response evaluation with CT (with or without FDG-PET) will take place at least every 12 weeks.
Adverse events will be evaluated at every visit, which is in week 2, 4 and 8 and every 4 to 12 weeks thereafter. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the last patient’s last visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |